



(51) International Patent Classification:

A61P 29/00 (2006.01) A61P 31/00 (2006.01)
A61K 8/64 (2006.01) A61Q 19/00 (2006.01)
A61K 38/00 (2006.01) C07K 7/06 (2006.01)
A61K 47/44 (2017.01) C07K 7/08 (2006.01)

(21) International Application Number:

PCT/CN2024/100923

(22) International Filing Date:

24 June 2024 (24.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/101989

22 June 2023 (22.06.2023)

CN

(71) Applicant: **ENLITISA (SHANGHAI) PHARMA-
CEUTICAL CO., LTD.** [CN/CN]; Room 201, 202, 203,
Building A, Block 1, No. 800, Qingdai Road, Pudong New
Area, Shanghai 201318 (CN).

(72) Inventors: **HAEGGSTROM, Jesper**; Department of
Medical Biochemistry And Biophysics, Karolinska Insti-
tute, SE-171 77 Stockholm (SE). **GU, Ming**; Room 201,
202, 203, Building A, Block 1, No. 800, Qingdai Road,

Pudong New Area, Shanghai 201318 (CN). **SONG, Mao-
qian**; Room 201, 202, 203, Building A, Block 1, No. 800,
Qingdai Road, Pudong New Area, Shanghai 201318 (CN).
KANG, Ruijuan; Room 201, 202, 203, Building A, Block
1, No. 800, Qingdai Road, Pudong New Area, Shanghai
201318 (CN).


(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 4, Yard 38,
Lin Feng ErLu Road, Greenland Central Square, Haidian
District, Beijing 100089 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: NEW MULTI-FUNCTIONAL OLIGOPEPTIDES

L-Q^a-D_b (I)



(II)




Figure 2

(57) Abstract: There is provided a compound of Formula I, where-
in: Q^a represents Z or A-Q-B, and Q is a structural fragment of For-
mula II, wherein: the squiggly lines, R and m have meanings given
in the description, and wherein A and B have meanings given in the
description, but may represent a peptide component of Formula (IV),
[(W)_r-Lys-X¹-T-U-X²-Y]_n- (W)_r-Lys-X¹-T-U-X²-Y (IV) (SEQ ID
No: 1) in which n, r, T, W, X¹, U, X² and Y have meanings given
in the description, each L independently represents a lipid as defined
in the description, and D represents one or more optional mon-
otelukast moieties, which compounds are useful in medicine, includ-
ing as pharmaceutical excipients, adhesives and film-forming materi-
als and/or are useful in the treatment of conditions characterised
by inflammation, including wounds, burns, and disorders of the mu-
cosa, such as anorectal diseases, inflammatory bowel diseases, gy-
necological diseases and dental diseases.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*